Skip Navigation



Alcohol and Alcoholism Advance Access published online on March 29, 2005
Alcohol and Alcoholism, doi:10.1093/alcalc/agh151
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
40/3/227    most recent
agh151v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by RUBIO, G.
Right arrow Articles by PALOMO, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by RUBIO, G.
Right arrow Articles by PALOMO, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Alcohol & Alcoholism © Medical Council on Alcohol 2005; all rights reserved
Received September 6, 2004
Revised January 12, 2005
Accepted March 7, 2005

Article

CLINICAL PREDICTORS OF RESPONSE TO NALTREXONE IN ALCOHOLIC PATIENTS: WHO BENEFITS MOST FROM TREATMENT WITH NALTREXONE?

G. RUBIO 1*, G. PONCE 2, R. RODRÍGUEZ-JIMÉNEZ 2, M. A. JIMÉNEZ-ARRIERO 2, J. HOENICKA 2, and T. PALOMO 2

1 Alcoholism Research Program, Servicios de Salud Mental, Retiro, Madrid, Spain
2 Unidad de Conductas Adictivas (UCA), Servicio de Psiquiatría, Hospital Universitario 12 de Octubre, Madrid, Spain

* To whom correspondence should be addressed.
G. RUBIO, E-mail: garuva{at}inicia.es


  Abstract

Aims: To determine the clinically ascertained variables that are related to satisfactory response to naltrexone (NTX) treatment of alcohol dependence after detoxification. Methods: The use of intake and outcome variables were measured in a randomized 3-month open-controlled trial comparing the effects of naltrexone plus psychotherapy treatment versus psychotherapy treatment alone on the maintenance of abstinence in the final 28 days (n = 336, all male). Results: Predictors of a positive response to NTX treatment were family history of alcoholism (P = 0.010), early age at onset of drinking problems (P = 0.014) and comorbid use of other drugs of abuse (P < 0.001). Among the subjects not treated with NTX, the greater the number of predictor variables, the lower the final 28 days abstinence rates (P = 0.00003), but this was not the case in patients treated with NTX (P = 0.844). Conclusions: Patients with these features, suggesting biological vulnerability overall have poorer outcomes, but this can be reduced with NTX treatment. The type of alcoholism should be considered before deciding on the pharmacological strategy.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Arch Gen PsychiatryHome page
C. S. Barr, M. Schwandt, S. G. Lindell, S. A. Chen, D. Goldman, S. J. Suomi, J. D. Higley, and M. Heilig
Association of a Functional Polymorphism in the {micro}-Opioid Receptor Gene With Alcohol Response and Consumption in Male Rhesus Macaques
Arch Gen Psychiatry, March 1, 2007; 64(3): 369 - 376.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.